Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2021
Dyadic and Janssen announce research, license and collaboration agreement
Dyadic announced that it entered into a research, license and collaboration agreement with Janssen for use of Dyadic’s C1 platform to develop production cell lines for Janssen therapeutic protein candidates.
2021
FDA approves Kyprolis combination regimen for multiple myeloma
The FDA approved a combination regimen of carfilzomib (Kyprolis), subcutaneous daratumumab and dexamethasone for adults with multiple myeloma who had received up to three previous lines of therapy.
2021
Philochem enters small-molecule discovery collaboration with Janssen
Philogen announced that its wholly owned Swiss subsidiary, Philochem, entered into a collaboration and option agreement with Janssen Biotech to discover small molecules using Philochem's lead-generation technologies. Janssen may exercise options to use identified ligands in further drug discovery and development.
2021
Mestag Therapeutics and Janssen enter target discovery and licensing agreement
Mestag Therapeutics announced a target discovery, option and license agreement with Janssen Biotech focused on identifying therapeutic targets in inflammatory disease.